The Rationale for FDA (and EMA) Regulatory Review of Tobacco Use in Clinical Trials

被引：0
|
作者：
Land, S. [1 ]
机构：
[1] NCI, Behav Res Program, Tobacco Control Res Branch, Bethesda, MD 20892 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
clinical trials; Smoking; cancer therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ES24.02
引用
收藏
页码：S90 / S91
页数：2
相关论文
共 50 条
  • [1] The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance
    Park, Jiyeon
    Huh, Ki Young
    Chung, Woo Kyung
    Yu, Kyung-Sang
    [J]. TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2024, 32 (01) : 41 - 51
  • [2] FDA OVERSIGHT OF CLINICAL TRIALS The US FDA and regulatory free fall
    Wilson, Mark
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
  • [3] THE IMPORTANCE OF OVERALL SURVIVAL AS A CLINICAL ENDPOINT IN FDA VS EMA REGULATORY APPROVAL
    Bustamante, M. M. D.
    Oshinowo, B.
    Subbotina, E.
    McGahan, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S91 - S91
  • [4] Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015
    Downing, Nicholas S.
    Zhang, Audrey D.
    Ross, Joseph S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14): : 1386 - 1387
  • [5] Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani, Saad
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    Eguale, Tewodros
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (07) : 709 - 715
  • [6] The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
    Gherghescu, Ioana
    Delgado-Charro, M. Begona
    [J]. PHARMACEUTICS, 2021, 13 (01) : 1 - 16
  • [7] Stem cells and the FDA: Regulatory considerations for proceeding to clinical trials
    Fink, Donald W., Jr.
    [J]. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2005, 41 : 7A - 7A
  • [8] Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective
    Refalo, Nathaniel
    Chetcuti, Daniel
    Tanti, Amy
    Serracino-Inglott, Anthony
    Borg, John Joseph
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2017, 25 (02) : 280 - 289
  • [9] Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS
    Kang, Su Lim
    Woo, Jae Hyun
    Kim, Na Hyeon
    Kwon, Ji Yean
    Kim, Sung Min
    [J]. MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 447 - 458
  • [10] Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvals
    Pinto, Cathy Anne
    Balantac, Zaneta
    Mt-Isa, Shahrul
    Liu, Xinyue
    Bracco, Oswaldo L.
    Clarke, Harrison
    Tervonen, Tommi
    [J]. DRUG DISCOVERY TODAY, 2023, 28 (10)
12345